Biopharma merger and acquisition value for the fourth quarter of 2020 reached $73.9bn from 49 transactions, a significant increase over Q3’s $43.2bn from 44 deals (see Exhibit 1). At the top (making up just over half of the Q4 total), was AstraZeneca’ s definitive agreement to acquire public rare disease drug developer Alexion Pharmaceuticals for $39bn. This deal, along with nine other Q4 M&A transactions topped the billion-dollar mark in Q4.
*NOTE: AT TIME OF PUBLICATION, THESE DEALS HAD NOT YET CLOSED.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?